G. Auerswald

发表

Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs

V. Jiménez‐Yuste, G. Benson, T. Lambert, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients

A. Duffy, C. Hermans, V. Jiménez‐Yuste, 2018, European journal of haematology.

Clinical manifestations, management, and molecular genetics in congenital factor VII deficiency: the International Registry on Congenital Factor VII Deficiency (IRF7)

G. Mariani, F. Bernardi, J. Schved, 2000, Blood.

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)

C. Djambas Khayat, G. Iosava, I. Romashevskaya, 2020, Journal of blood medicine.

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)

O. Stasyshyn, T. Rogosch, W. Seifert, 2020, Journal of blood medicine.

Thrombosis in inherited factor VII deficiency

J. Astermark, G. Mariani, F. Bernardi, 2003, Journal of thrombosis and haemostasis : JTH.

Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene

J. Astermark, S. Schulman, A. Batorova, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene

A. Batorova, H. Pollmann, A. Ruiz-Sáez, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Evaluation of pharmacokinetics, efficacy and safety of Immunate® solvent detergent in previously treated patients with severe haemophilia A

H. Ehrlich, A. Klukowska, V. Komrska, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics, Efficacy and Safety of IMMUNATE® Solvent/Detergent (IMMUNATE® S/D) in Previously Treated Patients with Severe Hemophilia A: Results of a Prospective, Multicenter, Open-Label Phase III Study

H. Ehrlich, A. Klukowska, V. Komrska, 2008, Acta Haematologica.

PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors.

V. Jiménez‐Yuste, T. Lambert, M. Morfini, 2012, Thrombosis Research.

When should prophylaxis therapy in inhibitor patients be considered?

V. Jiménez‐Yuste, T. Lambert, M. Morfini, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER)

A. Chuansumrit, G. Mariani, P. Charoenkwan, 2013, Haematologica.

Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A

M. Recht, A. Thompson, R. Liesner, 2012, Thrombosis and Haemostasis.

Prevalence and outcome of intracranial haemorrhage in haemophiliacs – a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH)

W. Kreuz, H. Brackmann, G. Auerswald, 1999, European Journal of Pediatrics.

Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency.

F. Peyvandi, R. Liesner, K. Kavaklı, 2021, Blood reviews.

The burden of inhibitors in haemophilia patients

V. Jiménez‐Yuste, S. Grancha, G. Auerswald, 2016, Thrombosis and Haemostasis.

Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients

V. Jiménez‐Yuste, G. Benson, T. Lambert, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical Efficacy and Safety of Wilate®, A New Generation, High-Purity VWF/FVIII-Concentrate with Optimized Pharmacokinetic Properties in the Treatment of Von Willebrand Disease.

J. Windyga, O. Walter, G. Auerswald, 2005 .

Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies

A. Chuansumrit, G. Mariani, G. Auerswald, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect

G. Mariani, F. Bernardi, G. Auerswald, 2014, Thrombosis and Haemostasis.

The EPIC Study: A Clinical Trial To Assess Whether Early Low Dose Prophylaxis In The Absence Of Immunological Danger Signals Reduces Inhibitor Incidence In Previously Untreated Patients (PUPs) With Hemophilia A

J. Blatny, K. Kurnik, G. Auerswald, 2013 .

Homozygous Factor X gene mutations Gly380Arg and Tyr163delAT are associated with perinatal intracranial hemorrhage.

G. Auerswald, K. Wulff, F. Herrmann, 2005, The Journal of pediatrics.

Absence of hepatitis A after treatment with pasteurised factor VIII concentrates in children with haemophilia A and von Willebrand disease

W. Kreuz, G. Auerswald, L. Gürtler, 1993, The Lancet.

Characterization of a Mutation in Exon 1 of the FVII Gene — a Case of RNA Editing?

G. Auerswald, K. Wulff, F. Herrmann, 2008 .

Therapeutical Options for Congenital FVII Deficiency — The HK 7 Project of the International Greifswald Registry of the Congenital FVII Deficiency (GR-HK-7)

G. Auerswald, J. Ingerslev, K. Wulff, 2008 .

Invasive procedures and minor surgery in factor VII deficiency

G. Mariani, A. Tagliaferri, G. Auerswald, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Patient-to-patient transmission of hepatitis C virus.

W. Kreuz, G. Auerswald, B. Kornhuber, 1995, Lancet.

Characterization of a Novel Aberrant Splice Site, 79bp Downstream of Exon 5 in the Human Factor 7 Gene Detected in Patients with Severe Congenital Factor VII Deficiency.

J. Astermark, G. Auerswald, K. Wulff, 2009 .

Secondary Prophylaxis with rFVIIa Improves Quality of Life of Hemophilia Patients with Inhibitors and Frequent Bleeds.

R. Ljung, B. Konkle, G. Auerswald, 2006 .

Homozygous Factor X Gene Mutation Gly380Arg is Associated to Perinatal Intracranial Hemorrhage

G. Auerswald, K. Wulff, F. Herrmann, 2005 .

German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies

W. Kreuz, H. Brackmann, G. Auerswald, 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitor Incidence in Previously Untreated Patients (PUP) with Hemophilia A and B - a 10-Year-Follow up of the Prospective Multicenter Study.

W. Kreuz, G. Auerswald, H. Lenk, 2004 .